Last reviewed · How we verify
ABT-888
ABT-888 is a PARP inhibitor Small molecule drug developed by AbbVie (prior sponsor, Abbott). It is currently in Phase 2 development for Metastatic breast cancer, triple-negative breast cancer, ovarian cancer. Also known as: ABT-888, veliparib, veliparib, Veliparib.
ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes.
Veliparib (ABT-888) is a small molecule PARP inhibitor used in cancer treatment. It has been studied in combination with paclitaxel and carboplatin for various types of cancer, including non-small cell lung cancer, leukemia, and lymphoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies. -
Big-pharma sponsor
+3.0pp
AbbVie (prior sponsor, Abbott) is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ABT-888 |
|---|---|
| Also known as | ABT-888, veliparib, veliparib, Veliparib |
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | PARP inhibitor |
| Target | PARP |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PARP enzymes, ABT-888 prevents DNA repair in cancer cells, leading to cell death. This mechanism is particularly effective in cancers with homologous recombination repair deficiencies.
Approved indications
- Metastatic breast cancer, triple-negative breast cancer, ovarian cancer
Common side effects
- Nausea
- Vomiting
- Fatigue
- Diarrhea
- Anemia
Key clinical trials
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (PHASE1)
- Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (PHASE2)
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE2, PHASE3)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (PHASE1)
- Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer (PHASE1)
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations (PHASE2)
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-888 CI brief — competitive landscape report
- ABT-888 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI
Frequently asked questions about ABT-888
What is ABT-888?
How does ABT-888 work?
What is ABT-888 used for?
Who makes ABT-888?
Is ABT-888 also known as anything else?
What drug class is ABT-888 in?
What development phase is ABT-888 in?
What are the side effects of ABT-888?
What does ABT-888 target?
Related
- Drug class: All PARP inhibitor drugs
- Target: All drugs targeting PARP
- Manufacturer: AbbVie (prior sponsor, Abbott) — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer, triple-negative breast cancer, ovarian cancer
- Also known as: ABT-888, veliparib, veliparib, Veliparib
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing